Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer

被引:34
作者
Andre, F. [1 ]
Nahta, R. [1 ]
Conforti, R.
Boulet, T.
Aziz, M.
Yuan, L. X. H. [1 ]
Meslin, F. [2 ]
Spielmann, M.
Tomasic, G.
Pusztai, L. [1 ]
Hortobagyi, G. N. [1 ]
Michiels, S.
Delaloge, S.
Esteva, F. J. [1 ]
机构
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Breast Med Oncol, Unit 1354, Houston, TX 77030 USA
[2] Inst Natl Sante & Rech Med U753, Lab Immunol Tumeurs Humaines, Inst Gustave Roussy, Villejuif, France
关键词
AKT; breast cancer; EGFR; HER2;
D O I
10.1093/annonc/mdm429
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: AKT phosphorylation is a critical step in the activation of growth factor receptors and can mediate tumor resistance to anthracyclines. We evaluated the expression patterns and predictive value of phosphorylated AKT (pAKT) in breast cancer tissues. Patients and methods: pAKT expression was assessed by immunohistochemistry in 823 tumors from patients with early breast cancer enrolled in two randomized trials. The distribution of pAKT expression was correlated with HER2 and epidermal growth factor receptor (EGFR) expression. The predictive value of pAKT for the efficacy of adjuvant chemotherapy was determined by test for interaction. Results: pAKT, EGFR, and HER2 were expressed in 119 of 781 (15%), 118 of 758 (16%), and 99 of 775 (13%) assessable tumors. Staining was positive for pAKT in 28 of 99 (28%) and 90 of 676 (13%) HER2+ and HER2- tumors (P < 0.001). pAKT was expressed in 15 of 94 (16%) and 75 of 563 (13%) HER2-/EGFR+ and HER2-/EGFR- tumors, respectively (P = 0.49). A positive staining for pAKT did not correlate with prognosis (P = 0.94), and did not predict the resistance to anthracyclines (test for interaction, P = 0.70). Conclusions: AKT phosphorylation is associated with HER2 expression but not EGFR expression in patients with early breast cancer. pAKT is not predictive for the efficacy of anthracycline-based adjuvant chemotherapy.
引用
收藏
页码:315 / 320
页数:6
相关论文
共 28 条
[1]   Perturbations of the AKT signaling pathway in human cancer [J].
Altomare, DA ;
Testa, JR .
ONCOGENE, 2005, 24 (50) :7455-7464
[2]   Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1 146 patients with early breast cancer [J].
Arriagada, R ;
Spielmann, M ;
Koscielny, S ;
Le Chevalier, T ;
Delozier, T ;
Rémé-Saumon, M ;
Ducourtieux, M ;
Tursz, T ;
Hill, C .
ACTA ONCOLOGICA, 2005, 44 (05) :458-466
[3]   Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer [J].
Baselga, J ;
Albanell, J ;
Ruiz, A ;
Lluch, A ;
Gascón, P ;
Guillém, V ;
González, S ;
Sauleda, S ;
Marimón, I ;
Tabernero, JM ;
Koehler, MT ;
Rojo, F .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5323-5333
[4]   Bad expression predicts outcome in patients treated with tamoxifen [J].
Cannings, Elizabeth ;
Kirkegaard, Tove ;
Tovey, Sian M. ;
Dunne, Barbara ;
Cooke, T. G. ;
Bartlett, John M. S. .
BREAST CANCER RESEARCH AND TREATMENT, 2007, 102 (02) :173-179
[5]   Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials [J].
Conforti, R. ;
Boulet, T. ;
Tomasic, G. ;
Taranchon, E. ;
Arriagada, R. ;
Spielmann, M. ;
Ducourtieux, M. ;
Soria, J. C. ;
Tursz, T. ;
Delaloge, S. ;
Michiels, S. ;
Andre, F. .
ANNALS OF ONCOLOGY, 2007, 18 (09) :1477-1483
[6]   THE IMPORTANCE OF HISTOLOGIC GRADE IN LONG-TERM PROGNOSIS OF BREAST-CANCER - A STUDY OF 1,010 PATIENTS, UNIFORMLY TREATED AT THE INSTITUT-GUSTAVE-ROUSSY [J].
CONTESSO, G ;
MOURIESSE, H ;
FRIEDMAN, S ;
GENIN, J ;
SARRAZIN, D ;
ROUESSE, J .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) :1378-1386
[7]  
COX DR, 1972, J R STAT SOC B, V34, P187
[8]   Lapatinib plus capecitabine for HER2-positive advanced breast cancer [J].
Geyer, Charles E. ;
Forster, John ;
Lindquist, Deborah ;
Chan, Stephen ;
Romieu, C. Gilles ;
Pienkowski, Tadeusz ;
Jagiello-Gruszfeld, Agnieszka ;
Crown, John ;
Chan, Arlene ;
Kaufman, Bella ;
Skarlos, Dimosthenis ;
Campone, Mario ;
Davidson, Neville ;
Berger, Mark ;
Oliva, Cristina ;
Rubin, Stephen D. ;
Stein, Steven ;
Cameron, David .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26) :2733-2743
[9]   Extranuclear expression of hormone receptors in primary breast cancer [J].
Kim, R. ;
Kaneko, M. ;
Arihiro, K. ;
Emi, M. ;
Tanabe, K. ;
Murakami, S. ;
Osaki, A. ;
Inai, K. .
ANNALS OF ONCOLOGY, 2006, 17 (08) :1213-1220
[10]   AKT activation predicts outcome in breast cancer patients treated with tamoxifen [J].
Kirkegaard, T ;
Witton, CJ ;
McGlynn, LM ;
Tovey, SM ;
Dunne, B ;
Lyon, A ;
Bartlett, JMS .
JOURNAL OF PATHOLOGY, 2005, 207 (02) :139-146